Abiopharma

News list

PROFOUND MEDICAL CORP. (PROF)

SEC News
May 07, 2026, 20:12 UTC

(90% Positive) PROFOUND MEDICAL CORP. (PROF) Reports Q2 2026 Financial Results

Full text

News bot May 7, 2026, 8:27 p.m.

📋 PROFOUND MEDICAL CORP. (PROF) - Financial Results

Filing Date: 2026-05-07

Accepted: 2026-05-07 16:12:39

Event Type: Financial Results

Event Details:

PROFOUND MEDICAL CORP. (PROF) Reports the reporting period Financial Results PROFOUND MEDICAL CORP. (PROF) announced its financial results for the period ending the reporting period. Key Financial Highlights:

Revenue: 88
Net Income: Not disclosed
EPS: Not disclosed
Cash and equivalents: $50
- PRO installed base stood at 80 at the end of Q1
- 2026, and the Company shipped an additional six (6) systems during the first quarter that had yet to be installed.In March 2026, Profound announced superiority on the prespecified, primary safety endpoint in the Level 1 post
- market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic radical prostatectomy in men with organ

📊 Key Financial Metrics (Year-over-Year Comparison):

Metric	2026	2025	Change ($)	Change (%)
Current Assets Property Equipment Net	682.00	682.00	$0.00	+0.00%
Current Assets Intangible Assets Net	129.00	129.00	$0.00	+0.00%
Current Liabilities Accounts Payable	2.14K	2.14K	$0.00	+0.00%
Operating Expenses Selling General Administrative	6.59K	6.59K	$0.00	+0.00%
Other Income Expenses Total Other Income Expense	993.00	993.00	$0.00	+0.00%
Property and Equipment, Net	682.00	682.00	$0.00	+0.00%
Intangible Assets, Net	129.00	129.00	$0.00	+0.00%
Accounts Payable	2.14K	2.14K	$0.00	+0.00%
Revenue	464.00	464.00	$0.00	+0.00%
Selling, General & Administrative	6.59K	6.59K	$0.00	+0.00%
Net Loss	7.03K	7.03K	$0.00	+0.00%

💼 Business Developments:

Partnership: Not available
Acquisition: Not available
Licensing: Not available
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: PROFOUND MEDICAL CORP.
Ticker Symbol: PROF